Could antidepressant treatment in rats with chronic aortic regurgitation modify intake and excretion of sodium?

• Grant number: 12/14482-4
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: November 01, 2012
• End date: October 31, 2013
• Field of knowledge: Biological Sciences - Physiology - Physiology of Organs and Systems
• Principal Investigator: Juliana Irani Fratucci de Gobbi
• Grantee: Mariana Franco Kumanaya
• Host Institution: Instituto de Biociências (IBB). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil

Abstract

Aortic regurgitation (AR) leads to left ventricle dilation and hypertrophy in response to a chronic volume overload. It is still very frequent in developing countries, such as Brazil, often as secondary to rheumatic fever. Its incidence has been increased as degenerative senile forms. Usually, chronic AR is generally well tolerated for many years, when with the heart dilated the patient search for treatment. Bidirectional association with depression and cardiovascular disease has been described. Selective serotonin reuptake inhibitors (SSRI) are widely prescribed to treat several affective disorders, especially for cardiovascular patients since they decrease arrhythmia probability. These SSRI improves cardiac function in rats submitted to stress protocols. In addition, there is an important central serotonergic pathway, located at the midbrain and pons, which decreases sodium and water intake. A preliminary study of our laboratory showed that subcrhonic AR (4 weeks after AR) following 4 weeks of treatment with one SSRI (paroxetine) in rats decreased daily sodium intake and improve systolic function. A question to be answered is if the SSRI treatment could be beneficial in animals with a chronic IAo(8 weeks after IAo). Therefore, the aims of the present project are to study the effects of the treatment with paroxetine from 8 to 12 weeks following AR on a) daily sodium and water intake, b) sodium and water intake following an acute fluid depletion, and c) urinary excretion of sodium and potassium after the SSRI treatment.(AU)